BR112022016948A2 - Enzimas para sialilação de glicanos - Google Patents

Enzimas para sialilação de glicanos

Info

Publication number
BR112022016948A2
BR112022016948A2 BR112022016948A BR112022016948A BR112022016948A2 BR 112022016948 A2 BR112022016948 A2 BR 112022016948A2 BR 112022016948 A BR112022016948 A BR 112022016948A BR 112022016948 A BR112022016948 A BR 112022016948A BR 112022016948 A2 BR112022016948 A2 BR 112022016948A2
Authority
BR
Brazil
Prior art keywords
sialylation
glycans
enzymes
nucleic acid
methods
Prior art date
Application number
BR112022016948A
Other languages
English (en)
Inventor
Meador James Iii
Freitas Pavao Sipsey Sandra
Medeiros Amy
Gurnani Srishti
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of BR112022016948A2 publication Critical patent/BR112022016948A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01022—Lactose synthase (2.4.1.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01038—Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99001—Beta-galactoside alpha-2,6-sialyltransferase (2.4.99.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ENZIMAS PARA SIALILAÇÃO DE GLICANOS. A presente invenção refere-se a proteínas de fusão, por exemplo, proteínas de fusão que compreendem uma porção(ões) enzimaticamente ativa(s) de ST6Gal1 ou B4GalT1, bem como métodos para produzir as mesmas, molécula(s) de ácido nucleico que codifica(m) a(s) proteína(s) de fusão, vetores que compreendem a(s) molécula(s) de ácido nucleico e célula(s) hospedeira(s) que compreende(m) o(s) vetor(es). A invenção também se refere a métodos de sialilação de anticorpos de imunoglobulina G (IgG).
BR112022016948A 2020-02-25 2021-02-25 Enzimas para sialilação de glicanos BR112022016948A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062981293P 2020-02-25 2020-02-25
US202063026927P 2020-05-19 2020-05-19
PCT/US2021/019607 WO2021173797A1 (en) 2020-02-25 2021-02-25 Enzymes for sialylation of glycans

Publications (1)

Publication Number Publication Date
BR112022016948A2 true BR112022016948A2 (pt) 2022-11-22

Family

ID=77490192

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016948A BR112022016948A2 (pt) 2020-02-25 2021-02-25 Enzimas para sialilação de glicanos

Country Status (11)

Country Link
US (1) US20230303984A1 (pt)
EP (1) EP4110391A1 (pt)
JP (1) JP2023515554A (pt)
KR (1) KR20220145877A (pt)
CN (1) CN115605230A (pt)
AU (1) AU2021226352A1 (pt)
BR (1) BR112022016948A2 (pt)
CA (1) CA3173252A1 (pt)
CO (1) CO2022013638A2 (pt)
MX (1) MX2022010467A (pt)
WO (1) WO2021173797A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240043838A (ko) * 2022-09-27 2024-04-04 크리포 주식회사 주요 아미노산이 전하성 및 소수성 아미노산으로 구성된 비정형 펩타이드 태그를 포함하여 자가 조립체를 형성하는 융합 단백질 및 이를 이용하여 재조합 단백질을 정제하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
ATE527371T1 (de) * 2005-03-24 2011-10-15 Biogenerix Ag Expression löslicher, aktiver, eukaryotischer glucosyltransferasen in prokaryotischen organismen
EP2900264A4 (en) * 2012-09-26 2016-05-25 Momenta Pharmaceuticals Inc GLYKOPROTEINZUBEREITUNGEN
EP2821482A1 (en) * 2013-07-05 2015-01-07 Roche Diagniostics GmbH N-terminally truncated glycosyltransferases
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
EP3083977B1 (en) * 2013-12-20 2018-02-28 F. Hoffmann-La Roche AG Improved recombinant polypeptide production methods
SG11201808457PA (en) * 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
US11674125B2 (en) * 2017-12-18 2023-06-13 The General Hospital Corporation Glycoengineering

Also Published As

Publication number Publication date
AU2021226352A1 (en) 2022-09-29
KR20220145877A (ko) 2022-10-31
EP4110391A1 (en) 2023-01-04
JP2023515554A (ja) 2023-04-13
CO2022013638A2 (es) 2022-10-21
US20230303984A1 (en) 2023-09-28
CN115605230A (zh) 2023-01-13
CA3173252A1 (en) 2021-09-02
WO2021173797A1 (en) 2021-09-02
MX2022010467A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
JP6463732B2 (ja) 上昇したレベルの外因性シャペロンを有する細胞抽出物を用いる細菌無細胞合成系における生物活性のあるタンパク質の発現
US11492650B2 (en) Production of seleno-biologics in genomically recoded organisms
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
Ren et al. Use of the SHuffle strains in production of proteins
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
Cesaratto et al. Engineered tobacco etch virus (TEV) protease active in the secretory pathway of mammalian cells
BR112018000477A2 (pt) proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural
CU23791A3 (es) Método para la producción de proteínas y anticuerpos mejorados
CN104837863A (zh) 用于提高表达的细菌提取物中选定蛋白的蛋白水解失活
BR112016018536A2 (pt) unidade de ultrafiltração para troca contínua de tampão ou meio a partir de uma solução de proteína.
Mueller et al. High level in vivo mucin-type glycosylation in Escherichia coli
Mamedov et al. In vivo production of non-glycosylated recombinant proteins in Nicotiana benthamiana plants by co-expression with Endo-β-N-acetylglucosaminidase H (Endo H) of Streptomyces plicatus
BR112022016948A2 (pt) Enzimas para sialilação de glicanos
BR112021025359A2 (pt) Composições de proteína anti-vegf e métodos para a produção das mesmas
Lauber et al. Expression of the functional recombinant human glycosyltransferase GalNAcT2 in Escherichia coli
BR112023003526A2 (pt) Proteínas de fusão de coronavírus imunogênicos e métodos relacionados
Tileva et al. Production of aggregation prone human interferon gamma and its mutant in highly soluble and biologically active form by SUMO fusion technology
Isticato et al. CotE binds to CotC and CotU and mediates their interaction during spore coat formation in Bacillus subtilis
KR20130020206A (ko) 수용성 ｂｍｐ-2를 생산하는 재조합 대장균 및 이를 이용한 수용성 ｂｍｐ-2의 제조방법
BR112021023438A2 (pt) Caracterização de variantes de carga específica de domínio de anticorpos
Lee et al. Simultaneous production of 2′‐fucosyllactose and difucosyllactose by engineered Escherichia coli with high secretion efficiency
Sun et al. Co-expression of Dsb proteins enables soluble expression of a single-chain variable fragment (scFv) against human type 1 insulin-like growth factor receptor (IGF-1R) in E. coli
US11041163B2 (en) Production of in vivo N-deglycosylated recombinant proteins by co-expression with endo H
Jung et al. Soluble expression of human leukemia inhibitory factor with protein disulfide isomerase in Escherichia coli and its simple purification
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.